FHTX

Foghorn Therapeutics Inc

Add to Watchlist

Advanced Chart

6.190

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

6.390

Open

6.210

VWAP

6.15

Vol

82.03K

Mkt Cap

345.04M

Low

6.000

Amount

504.67K

EV/EBITDA(TTM)

Total Shares

55.33M

124.45M

EV/OCF(TTM)

P/S(TTM)

15.80

Foghorn Therapeutics Inc. is a clinical-stage, precision therapeutics biotechnology company. The Company is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control platform, it is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is also developing multiple product candidates in oncology. The Gene Traffic Control platform provides an integrated and mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within this system. Its platform enables to produce components of the chromatin regulatory system at scale, thereby allowing to identify these genetic dependencies, understand their mechanism and target their vulnerabilities.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

7.64M

+167.67%

-0.335

+11.67%

7.34M

-5.95%

-0.332

+6.99%

7.10M

+3.03%

-0.318

-29.26%

Estimates Revision

The market is revising Downward the revenue expectations for Foghorn Therapeutics Inc. (FHTX) for FY2025, with the revenue forecasts being adjusted by -7.06% over the past three months. During the same period, the stock price has changed by 41.00%.

Revenue Estimates for FY2025

Revise Downward

-7.06%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+26.81%

In Past 3 Month

Stock Price

Go Up

+41.00%

In Past 3 Month

4 Analyst Rating

40.06% Upside

Wall Street analysts forecast FHTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FHTX is 8.67 USD with a low forecast of 4.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

40.06% Upside

Current: 6.190

Low

4.00

Averages

8.67

High

13.00

40.06% Upside

Current: 6.190

Low

4.00

Averages

8.67

High

13.00

JMP Securities

Silvan Tuerkcan

Buy

Initiates

2025-04-23

Reason

JMP Securities

Silvan Tuerkcan

Price Target

2025-04-23

Initiates

Buy

Reason

HC Wainwright & Co.

Andrew Fein

Strong Buy

Reiterates

$13

2025-03-07

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

$13

2025-03-07

Reiterates

Strong Buy

Reason

B. Riley Securities

Kalpit Patel

Strong Buy

Initiates

$10

2025-01-30

Reason

B. Riley Securities

Kalpit Patel

Price Target

$10

2025-01-30

Initiates

Strong Buy

Reason

HC Wainwright & Co.

Andrew Fein

Strong Buy

Reiterates

$20 → $13

2024-12-17

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

$20 → $13

2024-12-17

Reiterates

Strong Buy

Reason

Jefferies

Kelly Shi

Strong Buy

Maintains

$18 → $14

2024-12-16

Reason

Jefferies

Kelly Shi

Price Target

$18 → $14

2024-12-16

Maintains

Strong Buy

Reason

Morgan Stanley

Vikram Purohit

Hold

Maintains

$6 → $9

2024-09-24

Reason

Morgan Stanley

Vikram Purohit

Price Target

$6 → $9

2024-09-24

Maintains

Hold

Reason

Morgan Stanley raised the firm's price target on Foghorn Therapeutics to $9 from $6 and keeps an Equal Weight rating on the shares. The firm updated and makes current its model ahead of Q3 earnings and the Phase 1 FHD-286 dose escalation update expected for R/R AML in Q4 by incorporating the impact of the registered direct offering Foghorn conducted earlier this year and by updating its operating expense ramp expectations. FHD-286 represents Foghorn's most advanced pipeline program and the firm sees this update as a key event that could have the potential for a plus or minus 25%-50% impact on the shares, the analyst added.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Foghorn Therapeutics Inc (FHTX.O) is -4.37, compared to its 5-year average forward P/E of -4.64. For a more detailed relative valuation and DCF analysis to assess Foghorn Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.64

Current PE

-4.37

Overvalued PE

-2.61

Undervalued PE

-6.67

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.29

Current EV/EBITDA

-1.57

Overvalued EV/EBITDA

0.85

Undervalued EV/EBITDA

-5.42

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

84.77

Current PS

12.74

Overvalued PS

264.95

Undervalued PS

-95.42

Financials

Annual

Quarterly

FY2025Q1

YoY :

+17.86%

5.95M

Total Revenue

FY2025Q1

YoY :

-18.73%

-22.91M

Operating Profit

FY2025Q1

YoY :

-24.71%

-18.83M

Net Income after Tax

FY2025Q1

YoY :

-49.15%

-0.30

EPS - Diluted

FY2025Q1

YoY :

-18.51%

-24.00M

Free Cash Flow

FY2025Q1

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q1

YoY :

+18.20%

-407.85

FCF Margin - %

FY2025Q1

YoY :

-36.12%

-316.43

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

781.2K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

227.6K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

781.2K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

FHTX News & Events

Events Timeline

2025-05-14 (ET)

2025-05-14

07:03:29

Foghorn Therapeutics sees cash runway into 2027

2025-05-14

07:03:13

Foghorn Therapeutics reports Q1 EPS (30c), consensus (29c)

2025-05-01 (ET)

2025-05-01

07:19:34

Foghorn Therapeutics appoints Neil Gallagher, Stuart Duty to board

News

5.0

07-01Newsfilter

Flagship Pioneering Unveils Terrana Biosciences to Deliver Adaptive, Targeted Agricultural Solutions through a Novel RNA Technology Platform

5.0

05-12Newsfilter

Ted Myles Joins Cellarity as Chief Executive Officer

1.0

05-05Newsfilter

Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference

People Also Watch

Silence Therapeutics PLC

Angel Oak Mortgage REIT Inc

Cidara Therapeutics Inc

Hamilton Beach Brands Holding Co

Benitec Biopharma Inc

Norwood Financial Corp

24.620

USD

+1.53%

FAQ

What is Foghorn Therapeutics Inc (FHTX) stock price today?

The current price of FHTX is 6.19 USD — it has increased 0 % in the last trading day.

FHTX

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

FHTX News & Events

Events Timeline

News

People Also Watch

FAQ

What is Foghorn Therapeutics Inc (FHTX) stock price today?

What is Foghorn Therapeutics Inc (FHTX)'s business?

What is the price predicton of FHTX Stock?

What is Foghorn Therapeutics Inc (FHTX)'s revenue for the last quarter?

What is Foghorn Therapeutics Inc (FHTX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Foghorn Therapeutics Inc (FHTX)'s fundamentals?

How many employees does Foghorn Therapeutics Inc (FHTX). have?

What is Foghorn Therapeutics Inc (FHTX) market cap?